Antitumour efficacy of TRAIL: an immunotherapeutic approach for the treatment of skeletal malignancies

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/565357

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The most serious clinical problem with patients with solid tumours is metastasis to bone, which leads to complications that can cause erosion of the patient's quality of life, and eventually death. TRAIL is a new cancer therapeutic that selectively kills cancer cells while sparing normal cells. The use of TRAIL agonistic antibodies that do not bind OPG and have increased serum half life offers an exciting approach for the treatment of skeletal malignancies that is non toxic and safe.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $459,034.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Orthopaedics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Animal Models | Bone Metatstasis | Bone Metstases | Breast Cancer | Immunotherapy | Novel Therapeutics | Preclinical Animal Models | Skeletal Malignancies | TRAIL

Related Links